UCB's bispecific beats J&J's Stelara in psoriasis phase 3

UCB’s bimekizumab has beaten Johnson & Johnson’s Stelara in a phase 3 psoriasis trial. The bispecific inhibitor of IL-17A and IL-17F outperformed J&J’s blockbuster incumbent against an endpoint that tracked the proportion of patients achieving a 90% reduction in psoriasis symptoms.